Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard J. Duma is active.

Publication


Featured researches published by Richard J. Duma.


Annals of Internal Medicine | 1981

The Evolution of Pulmonary Cryptococcosis: Clinical Implications from a Study of 41 Patients With and Without Compromising Host Factors

Thomas M. Kerkering; Richard J. Duma; Smith Shadomy

Over 14 years 41 patients were diagnosed as having pulmonary cryptococcosis. Cryptococcus neoformans remained localized to the lung in 12 cases and disseminated in the remaining 29. Thirty-four patients were compromised hosts. Disseminated disease developed in 28 of these 34, and four of these 28 patients with disseminated disease presented with concomitant pulmonary and meningeal infections. In all the remaining 24 central nervous system involvement developed 2 to 20 weeks after the finding of an abnormal chest roentgenogram. Seven patients were normal hosts, and in six of these cases disease remained localized to the lung. Four important conclusions were drawn from this study: pulmonary cryptococcosis is rarely considered in the differential diagnosis of an abnormal chest roentgenogram, thereby leading to missed diagnoses and therapeutic errors; the natural history of untreated pulmonary cryptococcosis in compromised hosts is extrapulmonic dissemination; compromised hosts with pulmonary cryptococcosis should receive antifungal therapy because of a high propensity for dissemination; and normal hosts in whom dissemination has been excluded generally do not need antifungal therapy.


The American Journal of Medicine | 1985

Pneumonia treated with imipenem/cilastatin

Robert A. Salata; Ronald L. Gebhart; Darwin L. Palmer; Barbara H. Wade; W. Michael Scheld; Dieter H.M. Gröschel; Richard P. Wenzel; Gerald L. Mandell; Richard J. Duma

In an open, prospective, multicenter trial the efficacy and tolerance of imipenem/cilastatin for the treatment of bacterial pneumonia was investigated. Forty-three adults were studied: 29 with nosocomial and 14 with community-acquired infections. Significant underlying disease was present in 91 percent of patients. Nosocomial infection was frequently associated with endotracheal intubation (48 percent), prior antibiotic therapy (48 percent), and recent surgery (31 percent). Most frequent sputum isolates included Pseudomonas aeruginosa (10, all nosocomial), Hemophilus influenzae (10), Escherichia coli (eight), Staphylococcus aureus (seven), and Streptococcus pneumoniae (six). Treatment with imipenem/cilastatin was associated with clinical cure in 93 percent of patients. Two of three failures and one superinfection occurred in association with isolates of Pseudomonas aeruginosa resistant to imipenem. Overall, six of 10 strains of Pseudomonas aeruginosa isolated prior to therapy developed resistance to imipenem after an average of 10 days of therapy. Adverse effects occurred in nine patients (21 percent) and included one case of pseudomembranous colitis. Monotherapy with imipenem/cilastatin of serious lower respiratory tract infections was relatively safe and highly effective with the exception of disease associated with P. aeruginosa.


Antimicrobial Agents and Chemotherapy | 1976

In vitro susceptibility of pathogenic Naegleria and Acanthamoeba species to a variety of therapeutic agents.

Richard J. Duma; Ruth Finley

Six pathogenic strains of Naegleria fowleri, two of Acanthamoeba castellanii, and three of Acanthamoeba polyphaga were tested in vitro for susceptibility to a variety of potentially useful therapeutic agents. Minimal motility inhibitory concentrations and minimal inhibitory concentrations were determined by a technique of subculturing pure clones of amoebae in plastic tissue culture chamber slides containing liquid axenic media and serially diluted drug, incubating at 30°C for Acanthamoeba and at 37°C for Naegleria, and observing on an inverted microscope at 6 h for inhibition of motility and at 24 and 48 h for inhibition of growth. Drug concentrations were selected on the basis of fluid levels achievable in humans. Amphotericin B, clotrimazole, and miconazole were the most effective drugs against Naegleria, whereas polymyxin B sulfate and pentamidine isethionate were somewhat effective against pathogenic Acanthamoeba. Our results suggest that amphotericin B is the most effective agent against Naegleria, but few agents are effective against Acanthamoeba. Images


Pathology | 2010

Primary amebic meningoencephalitis.

Richard J. Duma; Harold W. Ferrell; E. Clifford Nelson; Muriel M. Jones

Abstract A healthy 15-year-old girl suffered fatal meningoencephalitis due to free-living amebas identified as naegleria. The organisms were cultured from cerebrospinal fluid, brain, lung, liver and spleen, and were seen in heart blood. Acute, diffuse myocarditis complicated by pulmonary edema occurred and was believed to be related to the infecting amebas. Primary amebic meningoencephalitis is being recognized with increased frequency and appears to be worldwide and capable of producing epidemics. Patients often give a history of swimming in fresh or brackish water, and the portal of entry may be the nasal mucosa. By means of appropriate technics, isolation of free-living amebas is relatively simple. All isolates (Florida, Virginia, Australia and Czechoslovakia) have been naegleria. The disease appears to be universally fatal and at present without promise of therapy.


The New England Journal of Medicine | 1979

Human infection from an unidentified erythrocyte-associated bacterium.

Gordon L. Archer; Philip H. Coleman; Roger M. Cole; Richard J. Duma; Charles L. Johnston

A 49-year-old splenectomized man had an infection from an unidentified, gram-positive, rod-shaped bacterium that adhered to the majority of his peripheral-blood erythrocytes. On transmission electron microscopy, the bacterium was seen to be extra-erythrocytic and was 0.2 micrometer wide by 1.0 to 1.7 micrometer long. It possessed a thick, granular cell wall, a trilamellar membrane external to the cell wall and prominent mesosomes. Attempts to cultivate the organism in vitro or to duplicate the patients disease in splenectomized animals were unsuccessful. The patients response suggested that the bacterium was susceptible to cell-wall-active antibiotics and to chloramphenicol but not to tetracycline. This bacterium may be the cause of other chronic, fever-producing, multisystem diseases of unknown origin.


Antimicrobial Agents and Chemotherapy | 1978

Comparison of Cephalothin and Cefamandole Prophylaxis During Insertion of Prosthetic Heart Valves

Gordon L. Archer; Ron E. Polk; Richard J. Duma; Richard R. Lower

Cefamandole nafate (CM) and cephalothin sodium (CP) were administered as prophylaxis in a randomized, prospective study to 30 consecutive patients undergoing prosthetic cardiac valve insertion. A single dose of 20 mg/kg was given intramuscularly during anesthesia induction, and serial plasma antibiotic concentrations, atrial muscle and cardiac valve tissue antibiotic levels, plasma bactericidal activity against pathogenic staphylococci, and infectious complications were determined and compared for the two drugs. Both antibiotics produced high plasma levels (>20 μg/ml 30 min after injection) which fell less than 25% during the period of cardiopulmonary bypass. However, CM levels were significantly higher at most time periods (P<0.05) than CP levels. CP levels were undetectable in atrial muscle from 14 of 15 patients and in valves from 10 of 15 patients. In contrast, CM bioactivity was found in all tissues. Differences in tissue antibiotic concentration could not be accounted for by differences in plasma concentrations or by CP tissue binding and were assumed to be caused by differences in penetration. Plasma bactericidal activity against staphylococci was equal for the two drugs (median titer, 1:16). No infections were seen in either group. CM appeared to be an effective and perhaps preferable prophylactic antibiotic for use during cardiac surgery.


Antimicrobial Agents and Chemotherapy | 1978

Therapeutic Failures with Miconazole

John F. Fisher; Richard J. Duma; Sheldon M. Markowitz; Smith Shadomy; Ana Espinel-Ingroff; William H. Chew

A retrospective review of therapeutic failures of miconazole in three patients is presented. Miconazole, a new imidazole derivative, is a broad-spectrum antifungal agent purportedly effective topically, orally, and parenterally against a number of species of fungi. Three patients with the following culturally proven deep fungal infections were treated with miconazole: (i) destructive arthritis (Sporothrix schenckii), (ii) meningoencephalitis (Cryptococcus neoformans), and (iii) disseminated aspergillosis (Aspergillus fumigatus). All the organisms were susceptible in vitro to 1.56 μg or less of miconazole per ml using a broth dilution technique. In each patient, miconazole administered intravenously in dosages of 30 mg/kg per day failed to control or eradicate infection. Miconazole serum levels ranged from <0.5 to 4.35 μg/ml as determined by radial diffusion bioassay. Cerebrospinal fluid levels were virtually undetectable. In one patient (C. neoformans), miconazole was given intraventricularly in doses of 15 mg without response. Therapeutic failures were attributed to suboptimal body fluid levels of miconazole. The reason(s) for such low levels of activity was not clear, but may have been poor penetrance into tissues, in vitro inactivation, and/or unusually rapid excretion. Untoward reactions from miconazole included fever, chills, nausea, vomiting, and phlebitis. Images


American Journal of Surgery | 1988

Cephalosporin therapy in intraabdominal infections: A multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin

Samuel E. Wilson; John A. Boswick; Richard J. Duma; Roger M. Echols; Joseph G. Jemsek; Robert Lerner; Ronald T. Lewis; Ahmad Z. Najem; Robert Press; Max S. Rittenbury; H. Harlan Stone; Gia T. Ton

Three broad-spectrum cephalosporins (cefotetan, moxalactam, and cefoxitin) proved effective in this randomized, prospective trial for treatment of 303 surgical patients with moderately severe regional peritonitis.


The American Journal of Medicine | 1976

Endocarditis due to accidental penetrating foreign bodies

Sheldon M. Markowitz; Szabolcs Szentpetery; Richard R. Lower; Richard J. Duma

A 15 year old boy had an eight month history of recurrent fever, malaise and poor appetite. Chest roentgenogram revealed a foreign object overlying the right ventricle. Multiple blood cultures grew Enterobacter cloacae. The patients condition improved and blood cultures became negative following gentamicin and carbenicillin therapy. E. cloacae was isolated from the foreign body (a finishing nail) at surgery. Antimicrobial therapy was continued for a total of 30 days, and the patient made an uneventful recovery.


The American Journal of Medicine | 1985

Gram-negative bacillary infections:Pathogenic and pathophysiologic correlates

Richard J. Duma

Gram-negative bacillary infections continue to be extremely important. Escherichia coli is the single most frequently encountered pathogen, followed by organisms belonging to the tribe Klebsiella-Enterobacter-Serratia and Proteus-Providencia. Pseudomonas aeruginosa, although it receives considerable (perhaps excessive) attention, is found relatively less frequently, occurring principally in the hospitalized patient who is immunocompromised. Many factors, both host and microbial, are responsible for invasiveness, virulence, and pathogenicity of gram-negative bacilli, but their relative roles, importance, and the pathophysiologic reactions they trigger are yet to be precisely defined. Certain aspects of many (but certainly not all) of the pathogenic correlates considered important in gram-negative bacillary infections, such as microbial flora, local barriers, surface and serum antibodies, complement, cell-mediated immunity, slime production, capsules, pili, endotoxin, cell wall components, extracellular products, and inoculum size are discussed herein. Points at which preventive or therapeutic strategies might be developed are offered. The benefits of antibiotics in managing susceptible gram-negative bacillary infections appear to be plateauing. If further advances are to be made in the therapy of these infections, new approaches to rapidly identifying the responsible etiologic agent and a better understanding of the factors responsible for invasiveness, virulence, and pathogenicity are needed.

Collaboration


Dive into the Richard J. Duma's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ahmad Z. Najem

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fred C. Tenover

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Gordon L. Archer

Virginia Commonwealth University

View shared research outputs
Top Co-Authors

Avatar

Grayson B. Miller

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

John F. Fisher

Georgia Regents University

View shared research outputs
Researchain Logo
Decentralizing Knowledge